Bio-Techne (TECH) SEC Filings: History & Chart

Bio-Techne Corporation(TECH)

Biotechnology · Minneapolis, MN

$72.61+0.04 (+0.06%)

Delayed quote: Sep 25, 2026, 4:00 PM EDT

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN

3,000 employees

www.bio-techne.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kim Kelderman

View full financials

Form	Filing Date	Accepted	Document
DEFA14A	Sep 9, 2026	Sep 9, 2026	View filing
DEFA14A	Sep 2, 2026	Sep 2, 2026	View filing
DEFA14A	Aug 25, 2026	Aug 25, 2026	View filing
10-K	Aug 24, 2026	Aug 24, 2026	View filing
DEFM14A	Aug 20, 2026	Aug 20, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
8-K	Aug 12, 2026	Aug 12, 2026	View filing
PREM14A	Aug 10, 2026	Aug 10, 2026	View filing
SC 13G/A	Aug 6, 2026	Aug 6, 2026	View filing
4	Jul 31, 2026	Jul 31, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 27, 2026	Jul 27, 2026	View filing
DEFA14A	Jul 9, 2026	Jul 9, 2026	View filing
8-K	Jun 26, 2026	Jun 25, 2026	View filing
DEFA14A	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing
SD	Jun 1, 2026	Jun 1, 2026	View filing
4	May 12, 2026	May 12, 2026	View filing

SEC Filings

Recent Filings